Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders ...

Over 2 million people were included in new research to test these drugs against 175 different health outcomes.

Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.

Maintaining weight loss after GLP-1 treatment is challenging — get expert tips on how to keep those pounds off for good.

GLP-1 weight loss drugs - such as Wegovy and Mounjaro - may reduce risk of conditions including Alzheimer’s disease and ...

including several newly found conditions linked to the GLP-1 class of weight loss and diabetes drugs. However, the new study led by Ziyad Al-Aly, a physician-scientist at the Veterans Affairs St ...

Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders. HealthDay News — For people with diabetes, the use of glucagon ...